These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

902 related articles for article (PubMed ID: 27641985)

  • 1. The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control.
    Bukh J
    J Hepatol; 2016 Oct; 65(1 Suppl):S2-S21. PubMed ID: 27641985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Replicons of a Rodent Hepatitis C Model Virus Permit Selection of Highly Permissive Cells.
    Wolfisberg R; Holmbeck K; Nielsen L; Kapoor A; Rice CM; Bukh J; Scheel TKH
    J Virol; 2019 Oct; 93(19):. PubMed ID: 31292246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C virus resistance to protease inhibitors.
    Halfon P; Locarnini S
    J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status and future development of infectious cell-culture models for the major genotypes of hepatitis C virus: Essential tools in testing of antivirals and emerging vaccine strategies.
    Ramirez S; Bukh J
    Antiviral Res; 2018 Oct; 158():264-287. PubMed ID: 30059723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
    Halfon P; Sarrazin C
    Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons.
    Yu M; Corsa AC; Xu S; Peng B; Gong R; Lee YJ; Chan K; Mo H; Delaney W; Cheng G
    Antiviral Res; 2013 Nov; 100(2):439-45. PubMed ID: 24013001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C Virus: 30 Years after Its Discovery.
    Houghton M
    Cold Spring Harb Perspect Med; 2019 Dec; 9(12):. PubMed ID: 31501269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from
    Sahuc ME; Sahli R; Rivière C; Pène V; Lavie M; Vandeputte A; Brodin P; Rosenberg AR; Dubuisson J; Ksouri R; Rouillé Y; Sahpaz S; Séron K
    J Virol; 2019 May; 93(10):. PubMed ID: 30842319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Animal model for hepatitis C virus infection].
    Tsukiyama-Kohara K; Kohara M
    Uirusu; 2015; 65(2):255-262. PubMed ID: 27760924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent hepatitis C viral replication despite priming of functional CD8+ T cells by combined therapy with a vaccine and a direct-acting antiviral.
    Callendret B; Eccleston HB; Satterfield W; Capone S; Folgori A; Cortese R; Nicosia A; Walker CM
    Hepatology; 2016 May; 63(5):1442-54. PubMed ID: 26513111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Future landscape of hepatitis C research - Basic, translational and clinical perspectives.
    Moradpour D; Grakoui A; Manns MP
    J Hepatol; 2016 Oct; 65(1 Suppl):S143-S155. PubMed ID: 27641984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Directly acting antivirals against hepatitis C virus.
    Soriano V; Vispo E; Poveda E; Labarga P; Martin-Carbonero L; Fernandez-Montero JV; Barreiro P
    J Antimicrob Chemother; 2011 Aug; 66(8):1673-86. PubMed ID: 21652618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in experimental systems to study hepatitis C virus in vitro and in vivo.
    Catanese MT; Dorner M
    Virology; 2015 May; 479-480():221-33. PubMed ID: 25847726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How Current Direct-Acting Antiviral and Novel Cell Culture Systems for HCV are Shaping Therapy and Molecular Diagnosis of Chronic HCV Infection?
    Maggi F; Focosi D; Pistello M
    Curr Drug Targets; 2017; 18(7):811-825. PubMed ID: 26245474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutting the gordian knot-development and biological relevance of hepatitis C virus cell culture systems.
    Gottwein JM; Bukh J
    Adv Virus Res; 2008; 71():51-133. PubMed ID: 18585527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insights into the unique characteristics of hepatitis C virus genotype 3 revealed by development of a robust sub-genomic DBN3a replicon.
    Ward JC; Bowyer S; Chen S; Fernandes Campos GR; Ramirez S; Bukh J; Harris M
    J Gen Virol; 2020 Nov; 101(11):1182-1190. PubMed ID: 32897181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targets for antiviral therapy of hepatitis C.
    Rupp D; Bartenschlager R
    Semin Liver Dis; 2014 Feb; 34(1):9-21. PubMed ID: 24782254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rational design of antiviral drug combinations based on equipotency using HCV subgenomic replicon as an in vitro model.
    Mandour M; Vliegen I; Paeshuyse J; Neyts J
    Antiviral Res; 2018 Jan; 149():150-153. PubMed ID: 29154807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transient replication of a hepatitis C virus genotype 1b replicon chimera encoding NS5A-5B from genotype 3a.
    Kylefjord H; Danielsson A; Sedig S; Belda O; Wiktelius D; Vrang L; Targett-Adams P
    J Virol Methods; 2014 Jan; 195():156-63. PubMed ID: 24120570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein.
    Belda O; Targett-Adams P
    Virus Res; 2012 Dec; 170(1-2):1-14. PubMed ID: 23009750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.